tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Bicara Therapeutics price target lowered to $41 from $44 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Bicara Therapeutics (BCAX) to $41 from $44 and keeps a Buy rating on the shares following the Q1 report

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1